Sensei Biotherapeutics (NASDAQ:SNSE) Issues Earnings Results, Hits Estimates

Sensei Biotherapeutics (NASDAQ:SNSE) announced its quarterly earnings results on Friday. The company reported ($0.27) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.27), Zacks reports.

Sensei Biotherapeutics Stock Performance

Shares of Sensei Biotherapeutics stock traded up $0.08 on Friday, hitting $0.51. The company had a trading volume of 145,672,542 shares, compared to its average volume of 898,433. Sensei Biotherapeutics has a 1 year low of $0.38 and a 1 year high of $1.94. The stock has a 50 day moving average of $0.47 and a 200-day moving average of $0.49. The stock has a market capitalization of $12.78 million, a price-to-earnings ratio of -0.43 and a beta of 0.16.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on SNSE shares. Oppenheimer upped their target price on Sensei Biotherapeutics from $3.50 to $4.00 and gave the stock an “outperform” rating in a research report on Friday. HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a report on Friday.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.